237 related articles for article (PubMed ID: 23433851)
1. Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia.
Camelo-Santos J; do Prado Barbosa A; de Paula Silveira-Lacerda E; Guillo LA
Biomed Pharmacother; 2013 Mar; 67(2):103-7. PubMed ID: 23433851
[TBL] [Abstract][Full Text] [Related]
2. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women.
Bhattacharya P; Sengupta S
Gynecol Oncol; 2005 Oct; 99(1):176-82. PubMed ID: 16054204
[TBL] [Abstract][Full Text] [Related]
3. Association of TP53 codon 72 polymorphism with cervical cancer risk in Chinese women.
Jiang P; Liu J; Zeng X; Li W; Tang J
Cancer Genet Cytogenet; 2010 Mar; 197(2):174-8. PubMed ID: 20193851
[TBL] [Abstract][Full Text] [Related]
4. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
5. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes.
Papadakis ED; Soulitzis N; Spandidos DA
Br J Cancer; 2002 Oct; 87(9):1013-8. PubMed ID: 12434294
[TBL] [Abstract][Full Text] [Related]
6. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
Ashariati A; Ugroseno S
Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
[TBL] [Abstract][Full Text] [Related]
7. Association of P53 codon 72 polymorphism and ameloblastoma.
Kitkumthorn N; Yanatatsaneejit P; Rabalert J; Dhammawipark C; Mutirangura A
Oral Dis; 2010 Oct; 16(7):631-5. PubMed ID: 20412452
[TBL] [Abstract][Full Text] [Related]
8. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
[TBL] [Abstract][Full Text] [Related]
9. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
Hu Y; McDermott MP; Ahrendt SA
Clin Cancer Res; 2005 Apr; 11(7):2502-9. PubMed ID: 15814626
[TBL] [Abstract][Full Text] [Related]
10. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
11. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk.
Damin AP; Frazzon AP; Damin DC; Roehe A; Hermes V; Zettler C; Alexandre CO
Cancer Detect Prev; 2006; 30(6):523-9. PubMed ID: 17113725
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
13. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia.
Hadhri-Guiga B; Toumi N; Khabir A; Sellami-Boudawara T; Ghorbel A; Daoud J; Frikha M; Gargouri A; Mokdad-Gargouri R
Cancer Genet Cytogenet; 2007 Oct; 178(2):89-93. PubMed ID: 17954263
[TBL] [Abstract][Full Text] [Related]
14. p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases.
Chen RH; Chang CT; Wang TY; Huang WL; Tsai CH; Tsai FJ
J Clin Lab Anal; 2008; 22(5):321-6. PubMed ID: 18803266
[TBL] [Abstract][Full Text] [Related]
15. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer.
Granja F; Morari J; Morari EC; Correa LA; Assumpção LV; Ward LS
Cancer Lett; 2004 Jul; 210(2):151-7. PubMed ID: 15183530
[TBL] [Abstract][Full Text] [Related]
16. TP53 gene polymorphisms at codons 11, 72, and 248 and association with endometriosis in a Brazilian population.
Camargo-Kosugi CM; D'Amora P; Kleine JP; Carvalho CV; Sato H; Schor E; Silva ID
Genet Mol Res; 2014 Aug; 13(3):6503-11. PubMed ID: 25177931
[TBL] [Abstract][Full Text] [Related]
17. TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis.
Zhuo XL; Cai L; Xiang ZL; Zhuo WL; Wang Y; Zhang XY
Arch Med Res; 2009 May; 40(4):299-305. PubMed ID: 19608020
[TBL] [Abstract][Full Text] [Related]
18. The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients.
Ignaszak-Szczepaniak M; Horst-Sikorska W; Sawicka J; Kaczmarek M; Slomski R
Oncol Rep; 2006 Jul; 16(1):65-71. PubMed ID: 16786124
[TBL] [Abstract][Full Text] [Related]
19. P53 (Pro72Arg) polymorphism associated with the risk of oral squamous cell carcinoma in gutka, niswar and manpuri addicted patients of Pakistan.
Saleem S; Azhar A; Hameed A; Khan MA; Abbasi ZA; Qureshi NR; Ajmal M
Oral Oncol; 2013 Aug; 49(8):818-23. PubMed ID: 23683469
[TBL] [Abstract][Full Text] [Related]
20. Analysis of polymorphisms in codons 11, 72 and 248 of TP53 in Brazilian women with breast cancer.
Almeida BC; Kleine JP; Camargo-Kosugi CM; Lisboa MR; França CN; França JP; Silva ID
Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26909997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
